NCT01856764已完成2 期
A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 40
- 主要终点
- Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)
研究概览
简要总结
The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is male or female between 18 to 65 years of age, inclusive, with atopic dermatitis (AD) meeting Hanifin and Rajka's criteria.
- •Has lesional skin areas of moderate severity characterized by modified local SCORing Atopic Dermatitis (SCORAD) of at least 4, with an erythema score ≥2, and confirmed by a qualified investigator.
- •Has an index/target lesion of moderate severity approximately 20 cm^2, suitable for topical treatment.
- •Is willing to wash out from AD current active therapy prior to entry in the study.
- •Is willing and able to apply the study medication as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
- •If a male who is nonsterilized and sexually active with a female partner of childbearing potential, agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
- •If a female of childbearing potential who is sexually active with a nonsterilized male partner, agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
- •Is capable of understanding and complying with protocol requirements in the opinion of the investigator.
- •Signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •Has received any investigational compound within 30 days, or within 5 half-lives of the compound (whichever is longer) prior to the Screening visit.
- •Has a history of AD unresponsive or poorly responsive to topical treatments.
- •Has a history of hypersensitivity to phosphodiesterase (PDE)-4 inhibitors or to drugs of similar chemical classes or any inactive ingredients of the trial medication.
- •Has clinically significant abnormal hematological parameters of hemoglobin, hematocrit or erythrocytes at Screening, in the judgment of the investigator.
- •Has a history or current clinically relevant allergy or idiosyncrasy to drugs or food.
- •Had extensive exposure to ultraviolet (UV) light in the 4 weeks prior to first application of study medication, including tanning and sun beds or is intending to have such exposure during the study treatment that may interfere with the study assessments as judged by the investigator.
- •Has evidence of oozing of target lesion.
- •Has a current skin complication such as erythroderma or overt bacterial or viral infection for which treatment with anti-infectives are indicated.
- •Had systemic treatment with corticosteroids or retinoids for studied condition within 3 months prior to the first application of study medication.
- •Had topical or transdermal treatments, such as but not limited to retinoids, nicotine or hormone replacement therapies, on or near the intended site of application within 4 weeks prior to first application of study medication.
- •Had treatment with systemic/locally acting medications/procedures that might counter or influence the study aim within 4 weeks prior to first application of study medication and during the study (e.g., anti-histamines).
- •Has used emollients/moisturizers on areas to be treated within 24 hours prior to the first application of study medication.
- •Has used biologics at any time for treatment of AD.
- •Is currently enrolled in an investigational drug or device study.
- •Has any clinically significant illness that may influence the outcome of the trial from 4 weeks before Day 1 through trial completion.
- •Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 × upper limit of normal (ULN), or other clinically significant abnormal laboratory test that, in the opinion of the Investigator, would compromise the participant's ability to safely complete the trial.
- •Has a significant medical condition and/or conditions that, in the opinion of the Investigator, would interfere with the treatment, safety or compliance with the protocol.
- •Has a history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- •Has a history of alcoholism or illicit drug abuse within 5 years prior to the Screening Visit or is currently consuming >14 alcoholic drinks per week.
- •If female, is pregnant, nursing or planning a pregnancy during the study period.
- •Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study medication. This criterion does not apply to those participants with successfully resected basal cell or stage I squamous cell carcinoma of the skin.
- •Has a chronic or clinically relevant acute infection.
- •Has a history of depression associated with suicidal ideation and behavior.
- •Has hemodynamically significant cardiac arrhythmias or heart valve deformations.
- •Is an immediate family member, a study site employee, in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or at risk for consenting under duress.
- •Was institutionalized because of a legal or regulatory order.
研究组 & 干预措施
0.5% Roflumilast Cream
Experimental
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
干预措施: 0.5% Roflumilast Cream (Drug)
Vehicle Cream
Placebo Comparator
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
干预措施: Vehicle Cream (Drug)
结局指标
主要结局
Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)
时间窗: Baseline and Day 15
Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.
次要结局
- Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values(Baseline and Day 15)
- Change From Baseline to Day 15 in Participants' Assessment of Pruritus(Baseline and Day 15)
研究者
相似试验
已完成
不适用
A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)COPDNCT01572948University of Alabama at Birmingham27
已完成
3 期
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseCOPDNCT01509677AstraZeneca158
终止
2 期
Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitisNonalcoholic SteatohapatitisNCT01703260AstraZeneca20
已完成
4 期
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)Chronic Obstructive Pulmonary DiseaseNCT01329029AstraZeneca1,945
已完成
2 期
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisPlaque PsoriasisNCT03638258Arcutis Biotherapeutics, Inc.331